A $10B deal, China trial scrutiny and highlights from ADA 2026
10 Jul 2026
24m
Fierce Life Sciences · Business
The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
Episodes
The deal before the deal
26 Jun 2026
41m
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
22 Jun 2026
20m
Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
12 Jun 2026
15m
Behind the headlines of ASCO 2026
05 Jun 2026
29m
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
03 Jun 2026
21m
Boston, China and the future of biotech
29 May 2026
35m
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
22 May 2026
12m
Health execs persevere in new policy landscape
15 May 2026
22m
Revisiting Pharma’s tariff reality
08 May 2026
15m
Scaling theranostics through access, safety and trust (Sponsored)
04 May 2026
7m
A pivotal time for an RNA pioneer
01 May 2026
35m
Accelerating clinical trials with precision logistics (Sponsored)
27 Apr 2026
7m
Can Trump’s deal with the UK become a model for similar drug price agreements?
24 Apr 2026
21m
Biomarkers are reshaping oncology trial design (Sponsored)
21 Apr 2026
14m
Fixing failed spray-dried formulations faster (Sponsored)
20 Apr 2026
32m
Roivant’s CEO thinks China is a ‘red herring’
17 Apr 2026
37m
The top 10 pharma R&D budgets of 2025
10 Apr 2026
13m
An update on the pharma industry’s reshoring effort
03 Apr 2026
21m
Pulse check on Lilly's GLP-1 fortunes
27 Mar 2026
16m
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.